China Approves Use Of Roche Arthritis Drug For Some Coronavirus Patients

China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe condition, health authorities said on Wednesday (March 4), as the country seeks to build up treatment regimens to help the infected recover. As per the latest guidelines published by National Health Commission, “Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients showing serious lung damage and an elevated level of a protein called Interleukin 6, which could indicate inflammation or immunological diseases.” There is no clinical trial evidence yet that the drug will be effective on coronavirus patients, however. Actemra also has not received approval from China's National Medical Product Administration to be sold for use for coronavirus infections. Chinese researchers recently registered a three-month clinical trial for Actemra that would recruit 188 coronavirus patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!